Cover Image
市場調查報告書

躁鬱症:日本的醫藥品市場預測與分析

Bipolar Disorder - Japan Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 365831
出版日期 內容資訊 英文 313 Pages
訂單完成後即時交付
價格
Back to Top
躁鬱症:日本的醫藥品市場預測與分析 Bipolar Disorder - Japan Drug Forecast and Market Analysis to 2024
出版日期: 2016年03月01日 內容資訊: 英文 313 Pages
簡介

本報告提供日本的躁鬱症治療藥臨床實驗趨勢與上市預測相關分析,躁鬱症概要和症狀、原因,目前的主要的治療方法,現在臨床實驗中的開發中產品的概要 (功效,SWOT分析等),市場規模預測 (今後11年份),主要的推動市場要素與其影響度等相關調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 疾病概要

  • 病因與病情
  • 分類
  • 症狀
  • 預後

第4章 疾病管理

  • 診斷方法概要
    • 臨床評估
    • 檢驗工具
  • 治療方法概要
    • 治療的開始與維持療法
    • 狂躁症、混合發作
    • 急性的興奮狀態
    • 輕率病發作
    • 重鬱症發作
    • 快速循環
    • 循環性情感症
    • 其他治療要素
  • 治療指南主要的處方藥
  • 日本

第5章 競爭產品的評估

  • 概要
  • 產品簡介和知名品牌
    • 抗痙攣藥
    • 典型抗精神病藥物
    • 非典型抗精神病藥物
    • 抗憂鬱劑
  • 其他治療層級

第6章 未滿足需求與市場機會

  • 概要
  • 躁鬱症的有效的治療選擇
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 錐體外路症狀 (EPS)、代謝變動的風險低的抗精神病藥
  • 安全性改善的心情穩定劑
  • 改善診斷率的醫生教育
  • 躁鬱症專用開發的新藥

第7章 開發中產品的評估

  • 概要
    • 診療各級臨床實驗趨勢
  • 臨床實驗階段的有希望醫藥品
    • Abilify Maintena
    • ITI-007
  • 非標籤藥物 (標示外使用) 開發中產品,與近來認證的治療藥
  • 臨床實驗的初期階段有潛力的醫藥品
  • 處於開發階段的其他醫藥品

第8章 市場未來展望

  • 日本
    • 預測
    • 近幾年主要的事件
    • 市場促進、阻礙因素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC274CFR

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka's Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

GlobalData estimates that drug sales for bipolar disorder in Japan reached $373.4m during 2014, making it the second largest market within the 8MM. The market is expected to grow starting from 2020, driven by the saturation of generic erosion and the uptake of novel pipeline agents.

Scope

  • Overview of Bipolar Disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Bipolar Disorder market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Bipolar Disorder.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Disease Management

  • 4.1. Diagnosis Overview
    • 4.1.1. Clinical Evaluation
    • 4.1.2. Screening Tools
  • 4.2. Treatment Overview
    • 4.2.1. Treatment Initiation and Maintenance Therapy
    • 4.2.2. Manic or Mixed Episodes
    • 4.2.3. Acute Agitation
    • 4.2.4. Hypomanic Episodes
    • 4.2.5. Major Depressive Episodes
    • 4.2.6. Rapid Cycling
    • 4.2.7. Cyclothymia
    • 4.2.8. Other Treatment Factors
  • 4.3. Treatment Guidelines and Leading Prescribed Drugs
  • 4.4. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles. Major Brands
    • 5.2.1. Lithium
    • 5.2.2. Anticonvulsants
    • 5.2.3. Typical Antipsychotics
    • 5.2.4. Atypical Antipsychotics
    • 5.2.5. Antidepressants
  • 5.3. Other Therapeutic Classes

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Effective Treatment Options for Bipolar Depression
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Antipsychotics with. Low Risk of EPS and Metabolic Changes
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Mood Stabilizers with Improved Safety Profiles
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Education for Physicians in Order to Improve Diagnosis Rates
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Novel Drugs Developed Specifically for Bipolar Disorder
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
    • 7.1.1. Clinical Trials by Class of Therapy
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Abilify Maintena
    • 7.2.2. ITI-007
  • 7.3. Off-label Pipeline and Recently Approved Therapies
  • 7.4. Promising Drugs in Early-Stage Development
  • 7.5. Other Drugs in Development

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Bipolar Disorder Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Launch and Patent Expiry Dates
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
  • 9.5. Primary Research. KOLs Interviewed for this Report
  • 9.6. Primary Research. Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Director of Therapy Research and Analysis
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM
  • Table 2: DSM-V Bipolar Disorder Specifiers
  • Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder
  • Table 4: Screening Tools Used for Bipolar Disorder
  • Table 5: Treatment Guidelines for Bipolar Disorder
  • Table 6: Most Prescribed Drugs for Bipolar Disorder by Episode Type in the Global Markets, 2014
  • Table 7: Country Profile - Japan
  • Table 8: Leading Treatments for Bipolar Disorder, 2015
  • Table 9: Product Profile - Lithium
  • Table 10: Lithium SWOT Analysis, 2015
  • Table 11: Global Sales Forecasts ($m) for Lithium, 2014-2024
  • Table 12: Product Profile - Carbamazepine
  • Table 13: Efficacy Results for Equetro in Bipolar Mania Trials
  • Table 14: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Equetro
  • Table 15: Carbamazepine SWOT Analysis, 2015
  • Table 16: Global Sales Forecasts ($m) for Carbamazepine, 2014-2024
  • Table 17: Product Profile - Lamotrigine
  • Table 18: Adverse Events at ≥5% Incidence in Bipolar Maintenance Trials of Lamictal
  • Table 19: Lamotrigine SWOT Analysis, 2015
  • Table 20: Global Sales Forecasts ($m) for Lamotrigine, 2014-2024
  • Table 21: Product Profile - Valproate
  • Table 22: Efficacy Results for Depakote in Bipolar Mania Trials
  • Table 23: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Depakote
  • Table 24: Valproate SWOT Analysis, 2015
  • Table 25: Global Sales Forecasts ($m) for Valproate, 2014-2024
  • Table 26: Typical Antipsychotics by Chemical Class
  • Table 27: Typical antipsychotics SWOT Analysis, 2015
  • Table 28: Global Sales Forecasts ($m) for the Typical Antipsychotics, 2014-2024
  • Table 29: Product Profile - Adasuve
  • Table 30: Efficacy Results for Adasuve in Agitation Trial of Bipolar I Disorder Patients
  • Table 31: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve
  • Table 32: Adasuve SWOT Analysis, 2015
  • Table 33: Global Sales Forecasts ($m) for Adasuve, 2014-2024
  • Table 34: Product Profile - Abilify
  • Table 35: Efficacy Results for Abilify in Bipolar Mania Trials
  • Table 36: Efficacy Results for Abilify in Agitation Trials
  • Table 37: Adverse Events at ≥2% Incidence in Bipolar I Disorder and Schizophrenia Trials of Abilify
  • Table 38: Abilify SWOT Analysis, 2015
  • Table 39: Global Sales Forecasts ($m) for Abilify, 2014-2024
  • Table 40: Product Profile - Geodon
  • Table 41: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Geodon
  • Table 42: Geodon SWOT Analysis, 2015
  • Table 43: Global Sales Forecasts ($m) for Geodon, 2014-2024
  • Table 44: Product Profile - Latuda
  • Table 45: Efficacy Results for Latuda in Bipolar Depression Trials
  • Table 46: Adverse Events at ≥2% Incidence in Bipolar Depression Trials of Latuda
  • Table 47: Latuda SWOT Analysis, 2015
  • Table 48: Global Sales Forecasts ($m) for Latuda, 2014-2024
  • Table 49: Product Profile - Risperdal
  • Table 50: Efficacy Results for Risperdal in Trial of Manic and Mixed Bipolar Episodes
  • Table 51: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Risperdal
  • Table 52: Adverse Events at ≥2% Incidence in Bipolar Maintenance Trials of Risperdal Consta
  • Table 53: Risperdal SWOT Analysis, 2015
  • Table 54: Global Sales Forecasts ($m) for Risperdal, 2014-2024
  • Table 55: Global Sales Forecasts ($m) for Risperdal Consta, 2014-2024
  • Table 56: Product Profile - Saphris
  • Table 57: Efficacy Results for Saphris in Bipolar Mania Studies
  • Table 58: Adverse Events at ≥2% Incidence in Bipolar I Disorder Trials of Saphris
  • Table 59: Saphris SWOT Analysis, 2015
  • Table 60: Global Sales Forecasts ($m) for Saphris, 2014-2024
  • Table 61: Product Profile - Seroquel
  • Table 62: Efficacy Results for Seroquel in Bipolar Mania Studies
  • Table 63: Efficacy Results for Seroquel in Bipolar Depression Trials
  • Table 64: Efficacy Results for Seroquel XR in Bipolar Disorder Trials
  • Table 65: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel
  • Table 66: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel XR
  • Table 67: Seroquel SWOT Analysis, 2015
  • Table 68: Global Sales Forecasts ($m) for Seroquel, 2014-2024
  • Table 69: Global Sales Forecasts ($m) for Seroquel XR, 2014-2024
  • Table 70: Product Profile - Symbyax
  • Table 71: Efficacy Results for Symbyax in Bipolar Depression Trials
  • Table 72: Adverse Events at ≥2% Incidence in Bipolar Depression and Treatment-Resistant Depression Trials of Symbyax
  • Table 73: Symbyax SWOT Analysis, 2015
  • Table 74: Global Sales Forecasts ($m) for Symbyax, 2014-2024
  • Table 75: Product Profile - Vraylar
  • Table 76: Vraylar SWOT Analysis, 2015
  • Table 77: Global Sales Forecast ($) for Vraylar, 2014-2024
  • Table 78: Product Profile - Zyprexa
  • Table 79: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Zyprexa
  • Table 80: Adverse Events at ≥2% Incidence in Trials of Zyprexa IntraMuscular in Agitation Associated with Schizophrenia or Bipolar I Mania
  • Table 81: Zyprexa SWOT Analysis, 2015
  • Table 82: Global Sales Forecasts ($m) for Zyprexa, 2014-2024
  • Table 83: Product Information for the Most Commonly Prescribed "Other Antipsychotics"
  • Table 84: International Society for Bipolar Disorders Clinical Recommendations for Antidepressant Use in Bipolar Disorder
  • Table 85: Antidepressants SWOT Analysis, 2015
  • Table 86: Global Sales Forecasts ($m) for the Antidepressants, 2014-2024
  • Table 87: Summary of Minor Therapeutic Classes, 2015
  • Table 88: Unmet Need and Opportunity in Bipolar Disorder
  • Table 89: Product Profile - Abilify Maintena
  • Table 90: Adverse Events at ≥2% Incidence in a Schizophrenia Trial of Abilify Maintena
  • Table 91: Abilify Maintena SWOT Analysis, 2015
  • Table 92: Global Sales Forecast ($) for Abilify Maintena, 2014-2024
  • Table 93: Product Profile - ITI-007
  • Table 94: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial
  • Table 95: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007
  • Table 96: ITI-007 SWOT Analysis, 2015
  • Table 97: Potential Off-label Bipolar Disorder Late-Stage Pipeline Drugs
  • Table 98: Drugs in Development, 2015
  • Table 99: Sales Forecasts ($m) for Bipolar Disorder in Japan, 2014-2024
  • Table 100: Key Events Impacting Sales for Bipolar Disorder in Japan, 2014-2024
  • Table 101: Bipolar Disorder Market in Japan - Drivers and Barriers, 2014-2024
  • Table 102: Key Launch Dates
  • Table 103: Key Patent Expiries
  • Table 104: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: The Etiology and Pathophysiology of Bipolar Disorders
  • Figure 2: The Effects of Lithium on Neurotransmission
  • Figure 3: The Effects of Lithium on Second Messenger Pathways
  • Figure 4: Bipolar Disorder Therapeutics - Class of Therapy, 2016
  • Figure 5: Bipolar Disorder - Phase II-III Pipeline, 2015
  • Figure 6: Clinical and Commercial Positioning of Abilify Maintena
  • Figure 7: Clinical and Commercial Positioning of ITI-007
  • Figure 8: Sales for Bipolar Disorder in Japan by Drug Class, 2014-2024
Back to Top